Deciphera Pharmaceuticals Inc $ 34.23 0.17 (0.5%)
Volume:
277,692
Avg Vol (1m):
770,202
Market Cap $:
1.73 Bil
Enterprise Value $:
1.51 Bil
P/E (TTM):
0.00
P/B:
5.90
| Net Current Asset Value | ||
| Tangible Book | ||
| Median P/S Value | ||
|
Price: $34.23 | ||
Manual of Stocks™ Web
Financial Strength | 7.8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 134.34 | ||
| Equity-to-Asset | 0.86 | ||
| Debt-to-Equity | 0.01 | ||
| Debt-to-EBITDA | -0.01 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 27.32 | ||
Profitability | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -526.88 | ||
| Net Margin % | -502.31 | ||
| ROE % | -45.39 | ||
| ROA % | -40.27 | ||
| ROC (Joel Greenblatt) % | -1136.77 | ||
| 3-Year EBITDA Growth Rate | -49.6 | ||
| 3-Year EPS without NRI Growth Rate | -43.8 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 5.9 | ||
| PS Ratio | 52.42 | ||
| EV-to-EBIT | -12 | ||
| EV-to-EBITDA | -12.06 | ||
| EV-to-Revenue | 60.4 | ||
| Current Ratio | 7.26 | ||
| Quick Ratio | 7.26 | ||
| Days Sales Outstanding | 292 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.86 | ||
| Price-to-Median-PS-Value | 1.46 | ||
| Earnings Yield (Greenblatt) % | -8.35 |